

SUPPLEMENTARY TABLE

Supplementary Table S1: Guardant360 54 gene cell-free DNA NGS panel

<i>ABL1</i>	<i>AKT1</i>	<i>ALK</i>	<i>APC</i>	<i>AR</i>	<i>ATM</i>
<i>BRAF</i>	<i>CDH1</i>	<i>CDKN2A</i>	<i>CSF1R</i>	<i>CTBBB1</i>	<i>EGFR</i> *
<i>ERBB2</i> *	<i>ERBB4</i>	<i>EZH2</i>	<i>FBXW7</i>	<i>FGFR1</i>	<i>FGFR2</i>
<i>FGFR3</i>	<i>FLT3</i>	<i>GNAI1</i>	<i>GNAQ</i>	<i>GNAS</i>	<i>HNFI1A</i>
<i>HRAS</i>	<i>IDH1</i>	<i>IDH2</i>	<i>JAK2</i>	<i>JAK3</i>	<i>KDR</i>
<i>KIT</i>	<i>KRAS</i>	<i>MET</i> *	<i>MLH1</i>	<i>MPL</i>	<i>MYC</i>
<i>NOTCH1</i>	<i>NPM1</i>	<i>NRAS</i>	<i>PDGFRA</i>	<i>PIK3CA</i>	<i>PTPN11</i>
<i>PTEN</i>	<i>PROC</i>	<i>RB1</i>	<i>RET</i>	<i>SMAD4</i>	<i>SMARCB1</i>
<i>SMO</i>	<i>SRC</i>	<i>STK11</i>	<i>TERT</i>	<i>TP53</i>	<i>VHL</i>

Complete exon coverage for genes in bold. Unbolded genes had critical exon coverage.

*Copy number amplification of *EGFR*, *ERBB2* (HER2) and *MET* genes was done (in addition of mutations (complete exon coverage)).